申请人:Takeda Pharmaceutical Company Limited
公开号:EP1886994A1
公开(公告)日:2008-02-13
A compound of the formula:
(wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+-R5 . Y- (R5 is a hydrocarbon group; Y- is a counter anion) ; R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group (s) other than oxo;G1 is a bond, CO or SO2 ; G2 is CO,S02, NHCO, CONH or OCO ; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group (s) whenGo ils a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in humans (e.g. AIDS).
式中的化合物:
(其中 R1 是氢原子、可被取代的烃基、可被取代的非芳香杂环基团,R2 是可被取代的烃基、可被取代的非芳香杂环基团,或 R1 和 R2 可与 A 相互结合形成可被取代的杂环基团;A 是 N 或 N+-R5 .Y-(R5 是烃基;Y- 是反阴离子);R3 是可被取代的环烃基或可被取代的杂环基;n 是 0 或 1;R4 是氢原子、可被取代的烃基、可被取代的杂环基、可被取代的烷氧基、可被取代的芳氧基或可被取代的氨基;E 是可被除氧代以外的基团(s)取代的二价脂肪族烃基;G1 是键、CO 或 SO2;G2 是 CO、S02、NHCO、CONH 或 OCO;J 是甲烷或氮原子;Q 和 R 各自是键或可被取代的二价 C1-3 脂肪族烃;条件是:当 G2 为 OCO 时,J 为甲烷;当另一个为键时,Q 和 R 中的一个不是键;当 Go ils 为键时,Q 和 R 中的每一个没有被氧化基团(s)取代)或其盐具有强效的 CCR5 拮抗活性,可有利地用于治疗或预防人类各种 HIV 感染性疾病(如艾滋病)。例如艾滋病)。